Boehringer Igelheim aims for top slot with anti-diabetes drug launch
With Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cardiology | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance | Pharmaceuticals